These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32853734)

  • 21. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas.
    Bochen F; Adisurya H; Wemmert S; Lerner C; Greiner M; Zimmermann R; Hasenfus A; Wagner M; Smola S; Pfuhl T; Bozzato A; Al Kadah B; Schick B; Linxweiler M
    Oncotarget; 2017 Jan; 8(3):4922-4934. PubMed ID: 28002801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suitability of GnRH Receptors for Targeted Photodynamic Therapy in Head and Neck Cancers.
    Pethő L; Murányi J; Pénzes K; Gurbi B; Brauswetter D; Halmos G; Csík G; Mező G
    Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma.
    Kakuki T; Kurose M; Takano K; Kondoh A; Obata K; Nomura K; Miyata R; Kaneko Y; Konno T; Takahashi S; Hatakeyama T; Kohno T; Himi T; Kojima T
    Oncotarget; 2016 Jun; 7(23):33887-900. PubMed ID: 27036044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteomics-based Predictive Model for the Early Detection of Metastasis and Recurrence in Head and Neck Cancer.
    Ribeiro IP; Esteves L; Anjo SI; Marques F; Barroso L; Manadas B; Carreira IM; Melo JB
    Cancer Genomics Proteomics; 2020; 17(3):259-269. PubMed ID: 32345667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ion Channel Dysregulation in Head and Neck Cancers: Perspectives for Clinical Application.
    Del-Río-Ibisate N; Granda-Díaz R; Rodrigo JP; Menéndez ST; García-Pedrero JM
    Rev Physiol Biochem Pharmacol; 2021; 181():375-427. PubMed ID: 32789787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
    Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of the expression and prognosis for CDCAs in head and neck squamous cell carcinoma.
    Wu ZH; Fang M; Zhou Y
    PLoS One; 2020; 15(7):e0236678. PubMed ID: 32716971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transient Receptor Potential (TRP) Channels in Head-and-Neck Squamous Cell Carcinomas: Diagnostic, Prognostic, and Therapeutic Potentials.
    Kiss F; Pohóczky K; Szállási A; Helyes Z
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32887395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Upregulation of the long non-coding RNA CASC9 as a biomarker for squamous cell carcinoma.
    Sassenberg M; Droop J; Schulz WA; Dietrich D; Loick SM; Wiek C; Scheckenbach K; Gaisa NT; Hoffmann MJ
    BMC Cancer; 2019 Aug; 19(1):806. PubMed ID: 31412811
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UBE2C promotes the progression of head and neck squamous cell carcinoma.
    Jin Z; Zhao X; Cui L; Xu X; Zhao Y; Younai F; Messadi D; Hu S
    Biochem Biophys Res Commun; 2020 Mar; 523(2):389-397. PubMed ID: 31870550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
    Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
    Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the PI3K Pathway in Head and Neck Squamous Cell Carcinoma.
    Isaacsson Velho PH; Castro G; Chung CH
    Am Soc Clin Oncol Educ Book; 2015; ():123-8. PubMed ID: 25993150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma.
    Diao P; Ge H; Song Y; Wu Y; Li J; Li Z; Yang J; Wang Y; Cheng J
    J Cell Mol Med; 2019 Jun; 23(6):4269-4280. PubMed ID: 30950191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downregulation of the circadian Period family genes is positively correlated with poor head and neck squamous cell carcinoma prognosis.
    Li YY; Jin F; Zhou JJ; Yu F; Duan XF; He XY; Wang R; Wu WL; Long JH; Luo XL
    Chronobiol Int; 2019 Dec; 36(12):1723-1732. PubMed ID: 31609143
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis.
    Zhang C; Qiao H; Guo W; Liu Y; Yang L; Liu Y; Jin B; Fu M; Wang G; Li W
    Cancer Lett; 2019 Jul; 455():1-13. PubMed ID: 30981760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative assessment of the effects of integrin inhibitor cilengitide on primary culture of head and neck squamous cell carcinoma (HNSCC) and HNSCC cell lines.
    Zhang L; Gülses A; Purcz N; Weimer J; Wiltfang J; Açil Y
    Clin Transl Oncol; 2019 Aug; 21(8):1052-1060. PubMed ID: 30632010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MERTK as a novel therapeutic target in head and neck cancer.
    von Mässenhausen A; Sanders C; Thewes B; Deng M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Heasley L; Brägelmann J; Perner S
    Oncotarget; 2016 May; 7(22):32678-94. PubMed ID: 27081701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel IFNα-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma.
    Ma H; Chang H; Yang W; Lu Y; Hu J; Jin S
    Mol Cancer; 2020 Jan; 19(1):4. PubMed ID: 31907020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.